Meeting
2017 ASCO Annual Meeting
Safety findings from FORWARD II: A phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer.
Authors
David M. O'Malley
The Ohio State University College of Medicine, Columbus, OH
David M. O'Malley , Kathleen N. Moore , Ignace Vergote , Lainie P. Martin , Lucy Gilbert , Antonio Gonzalez Martin , Dale L. Nepert , Rodrigo Ruiz-Soto , Michael J. Birrer , Ursula A. Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02606305
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5553)
DOI
10.1200/JCO.2017.35.15_suppl.5553
Abstract #
5553
Poster Bd #
375
Abstract Disclosures
Similar Posters
First Author: David M. O'Malley
Poster
2019 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
First Author: David M. O'Malley
Poster
2018 ASCO Annual Meeting
Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
First Author: David M. O'Malley
Poster
2022 ASCO Annual Meeting
PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
First Author: Judith Michels